As for middle range values (≥0.26 and <0.34) marking MS patients exhibiting a worse clinical outcome, these might be a result of IL-2 acting as a Th1 pathway activator, while suppressing Th17 differentiation. This evidence concerns the gene IL2 and myeloid sarcoma.